Literature DB >> 1406603

Nucleotide specificity of human deoxycytidine kinase.

D S Shewach1, K K Reynolds, L Hertel.   

Abstract

The ability of deoxycytidine kinase (dCK) to phosphorylate 2'-deoxycytidine (dCyd) and its analogs in the presence of eight nucleoside triphosphates (NTPs), simulating the cellular milieu, was investigated. Using highly purified dCK from MOLT-4 T lymphoblasts, Km and Vmax values were determined for the phosphorylation of dCyd in the presence of cellular concentrations of the eight endogenous NTPs. The results demonstrated that the efficiency of dCyd phosphorylation was greatest in the presence of all eight nucleotides, relative to ATP alone, according to relative Vmax/Km values. UTP was a better phosphate donor than ATP but was less efficient than the NTP mixture. The greater efficacy of the NTP mixture, compared with ATP alone, was due in large part to the presence of UTP, although the results suggested that the presence of other nucleotide(s) also enhanced dCyd phosphorylation. Previous results demonstrated that dCTP was a potent competitive or noncompetitive (with respect to dCyd) inhibitor of dCK, with a Ki value of approximately 1 microM. In contrast, the results presented here demonstrated that, in the presence of either the NTP mixture or UTP, inhibition of dCK was uncompetitive with respect to dCyd, with a Ki value of approximately 60 microM. Furthermore, the results demonstrated that the clinically relevant nucleoside analogs 1-beta-D-arabinofuranosylcytosine, 2',2'-difluoro-2'-deoxycytidine (dFdC), and 9-beta-D-arabinofuranosyl-2-fluoroadenine also preferred UTP or the NTP mixture, compared with ATP alone, as a phosphate donor. Of the three nucleoside analogs tested, dFdC was the most efficient dCK substrate. These data indicate that the preferred phosphate donor for dCK is UTP or a combination of UTP and another nucleotide. Furthermore, the dCTP concentration in intact cells, which is typically 10-20 microM, is not sufficient to cause substantial inhibition of dCK, due to the presence of UTP. Strategies to increase cellular dCK activity should focus on optimizing UTP concentrations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1406603

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  21 in total

1.  Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers.

Authors:  M Joerger; T M Bosch; V D Doodeman; J H Beijnen; P H M Smits; J H M Schellens
Journal:  Eur J Clin Pharmacol       Date:  2006-06-24       Impact factor: 2.953

2.  Post-translational phosphorylation of serine 74 of human deoxycytidine kinase favors the enzyme adopting the open conformation making it competent for nucleoside binding and release.

Authors:  Saugata Hazra; Andrzej Szewczak; Stephan Ort; Manfred Konrad; Arnon Lavie
Journal:  Biochemistry       Date:  2011-03-16       Impact factor: 3.162

Review 3.  Cellular and clinical pharmacology of fludarabine.

Authors:  Varsha Gandhi; William Plunkett
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Metabolism in human cells of the D and L enantiomers of the carbocyclic analog of 2'-deoxyguanosine: substrate activity with deoxycytidine kinase, mitochondrial deoxyguanosine kinase, and 5'-nucleotidase.

Authors:  L L Bennett; P W Allan; G Arnett; Y F Shealy; D S Shewach; W S Mason; I Fourel; W B Parker
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

5.  Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells.

Authors:  Tieran Han; Marilyn Fernandez; Ting-Chao Chou; Ram P Agarwal
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

6.  The sugar ring of the nucleoside is required for productive substrate positioning in the active site of human deoxycytidine kinase (dCK): implications for the development of dCK-activated acyclic guanine analogues.

Authors:  Saugata Hazra; Manfred Konrad; Arnon Lavie
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

7.  Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360).

Authors:  Godefridus J Peters; Kees Smid; Leonardo Vecchi; Ietje Kathmann; Dzjemma Sarkisjan; Richard J Honeywell; Nienke Losekoot; Osnat Ohne; Aric Orbach; Eran Blaugrund; Lak Shin Jeong; Young Bok Lee; Chang-Ho Ahn; Deog Joong Kim
Journal:  Invest New Drugs       Date:  2013-09-19       Impact factor: 3.850

8.  Elucidation of different binding modes of purine nucleosides to human deoxycytidine kinase.

Authors:  Elisabetta Sabini; Saugata Hazra; Manfred Konrad; Arnon Lavie
Journal:  J Med Chem       Date:  2008-06-21       Impact factor: 7.446

9.  Structural basis for substrate promiscuity of dCK.

Authors:  Elisabetta Sabini; Saugata Hazra; Stephan Ort; Manfred Konrad; Arnon Lavie
Journal:  J Mol Biol       Date:  2008-03-03       Impact factor: 5.469

10.  Automated mass action model space generation and analysis methods for two-reactant combinatorially complex equilibriums: an analysis of ATP-induced ribonucleotide reductase R1 hexamerization data.

Authors:  Tomas Radivoyevitch
Journal:  Biol Direct       Date:  2009-12-09       Impact factor: 4.540

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.